ProMIS Neurosciences is trading 5.4% down at $14.26 today, appearing to undergo profit-taking and consolidation following a sharp multi-day rally.
- The recent surge was driven by positive first human target-engagement data and clinical updates regarding the PMN310 Alzheimer’s program.
- With no new company-specific announcements today, the move is viewed as a natural retracement following significant gains.
- The stock's decline occurs despite a broadly positive backdrop across the biotech sector and wider equity markets.